Transplant Vasculopathy Versus Native Atherosclerosis: Similarities and Differences.

Area of Science:

• Cardiology
• Immunology
• Transplantation

Background:

• Cardiac allograft vasculopathy (CAV) is a primary driver of graft failure and mortality post-heart transplantation.
• Pathogenesis involves alloimmune and non-alloimmune factors activating recipient and donor immune systems.
• Early CAV diagnosis is difficult due to denervated heart ischemia, functional changes, insensitive angiography, and microvascular involvement.

Purpose of the Study:

• To elucidate the characteristics and challenges in diagnosing and managing Cardiac Allograft Vasculopathy (CAV).
• To differentiate CAV from native coronary atherosclerosis.
• To highlight the poor prognosis and limited treatment efficacy for CAV.

Main Methods:

• Review of existing literature on CAV pathogenesis, diagnosis, and comparison with native atherosclerosis.
• Analysis of clinical presentation and outcomes in heart transplant recipients versus native heart patients.

Main Results:

• CAV is a panarterial disease within the allograft, featuring intimal hyperplasia and medial disease.
• CAV plaque composition varies from fibrous to calcified, differing from focal native atherosclerosis.
• Heart transplant recipients with acute coronary syndromes face higher mortality and cardiogenic shock risk.

Conclusions:

• CAV presents unique diagnostic and therapeutic challenges compared to native coronary artery disease.
• The rapid, diffuse nature of CAV and its poor prognosis necessitate improved management strategies.
• Effective prevention and treatment strategies for CAV are urgently needed to improve long-term outcomes in heart transplant recipients.